Global Plasma Therapeutics Market 2015-2019


◆タイトル:Global Plasma Therapeutics Market 2015-2019
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆資料形式:pdf / 英語
Single UserUSD2,500 ⇒換算¥275,000見積依頼/購入/質問フォーム
Five UserUSD3,000 ⇒換算¥330,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD4,000 ⇒換算¥440,000見積依頼/購入/質問フォーム
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。



About plasma and plasma therapeutics
Plasma, pale yellow in color, is the component of the blood. It acts as a medium of transportation for the blood cells and other components. It carries salts and enzymes along with water and also transports nutrients, hormones, and other substances to the different parts of the body. Plasma contains immunoglobulins, clotting factors, albumin, and other components that can be used for the treatment of various diseases. The separation of plasma from the blood is done by a process known as plasmapheresis. Plasma therapeutics are utilized in the treatment of rare, life-threatening, chronic, and genetic diseases, such as immune deficiencies, pulmonary disorders, neurological disorders, shock and trauma, liver cirrhosis, and infectious diseases such as tetanus, hepatitis, and rabies.

Technavio’s analysts forecast the global plasma therapeutics market to grow at a CAGR of 12.10% over the period 2014-2019.

[Covered in this report]
The report covers the present scenario and the growth prospects of the global plasma therapeutics market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of branded therapies derived from the various fractions of plasma such as albumin, immunoglobulins, coagulation factors, hyperimmune globulins, and A1PI.

Technavio’s report, Global Plasma Therapeutics Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and EMEA; it also covers the landscape of the global plasma therapeutics market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

[Key regions]
• Americas

[Key vendors]
• Baxter
• CSL Behring
• Grifols Therapeutics
• Octapharma

[Other prominent vendors]
• Abeona Therapeutics
• ADMA Biologics
• Amag Pharmaceuticals
• Antares Pharma
• BioDelivery Sciences
• Bio Products Laboratory
• Biota Pharmaceuticals
• Biotest Pharmaceuticals
• China Biologic Products
• Depomed
• Emergent BioSolutions
• Ethicon
• Flamel Technologies
• Kamada
• Kedrion
• King Pharmaceuticals
• Nektar Therapeutics
• OMRIX Biopharmaceuticals
• ProMetic Life Sciences
• Rockwell Medical
• The Medicines
• ZymoGenetics

[Market Driver]
• Growing demand for IVIG therapies
• For a full, detailed list, view our report

[Market challenge]
• High cost of therapy
• For a full, detailed list, view our report

[Market trend]
• Patient assistance programs
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?


PART 01:Executive summary

PART 02:Scope of the report

PART 03:Market research methodology

PART 04:Introduction

PART 05:Plasma therapeutics: An overview:
Components of blood plasma
Process to derive plasma therapeutics
Clinical uses of plasma
Cost structure of plasma therapeutics

PART 06:Regulation of plasma therapeutics
Regulatory authorities

PART 07:Market landscape
Market overview
Market size and forecast
Five forces analysis

PART 08:Market segmentation by fractionation products of plasma
Human albumin
Plasma derived coagulation factors
Hyperimmune globulins
Global human albumin market 2014-2019
Global immunoglobulins market 2014-2019
Global A1PI market 2014-2019

PART 09:Market segmentation by disease type
Clotting disorders
Immune disorders

PART 10:Geographical segmentation

PART 11:Market drivers

PART 12:Impact of drivers

PART 13:Market challenges

PART 14:Impact of drivers and challenges

PART 15:Market trends

PART 16:Vendor landscape
Competitive scenario
Market share analysis 2014
Other prominent vendors

PART 17:Key vendor analysis
Baxter International Inc.
CSL Behring

PART 18:Appendix
List of abbreviation

[List of Exhibits]

Exhibit 01: Product offerings
Exhibit 02: Composition of blood
Exhibit 03: Composition of plasma
Exhibit 04: Total collection of plasma in US 2010-2014 (in liters)
Exhibit 05: Projected fractionation capacity of manufacturing units in US and EU (millions of liter/annum)
Exhibit 06: Process of procurement and manufacturing of plasma therapeutics
Exhibit 07: Regulatory policies of plasma protein therapy lifecycle
Exhibit 08: Global plasma therapeutics market 2014-2019 ($ billions)
Exhibit 09: Five forces analysis
Exhibit 10: Global plasma therapeutics market segment by fractionation products of plasma
Exhibit 11: Global human albumin market 2014-2019 ($ millions)
Exhibit 12: Key performance indicators of global albumin market
Exhibit 13: Global immunoglobulins market 2014-2019 ($ millions)
Exhibit 14: Key performance indicators of global immunoglobulin market
Exhibit 15: Global A1PI market 2014-2019 ($ millions)
Exhibit 16: Key performance indicators of global A1PI market
Exhibit 17: Global plasma therapeutics market segment by disease type
Exhibit 18: Segmentation of global plasma therapeutics market by geography 2014
Exhibit 19: Drivers of global plasma therapeutics market
Exhibit 20: Impact of drivers
Exhibit 21: Challenges of global plasma therapeutics market
Exhibit 22: Impact of drivers and challenges
Exhibit 23: Global plasma therapeutics market share analysis 2014
Exhibit 24: YoY growth and revenue generated by plasma therapeutics 2011-2014 ($ millions)
Exhibit 25: YoY growth and revenue generate 2011-2014 ($ millions)
Exhibit 26: YoY growth and revenue of bioscience division 2011-2014 ($ millions)
Exhibit 27: Share of revenue by different divisions in 2014
Exhibit 28: YoY growth and revenue of plasma therapeutics 2011-2014 ($ millions)
Exhibit 29: Baxter International Inc. : Business segmentation
Exhibit 30: Baxter International Inc.: Revenue by business segmentation 2013
Exhibit 31: Baxter International Inc.: Revenue by geographical segmentation 2013
Exhibit 32: CSL Behring: Therapeutic areas segmentation 2013
Exhibit 33: CSL Behring: Product portfolio
Exhibit 34: CSL Behring: Geographical segmentation by revenue 2013
Exhibit 35: Grifols: Business segmentation by revenue 2013
Exhibit 36: Grifols: Business segmentation by revenue 2012 and 2013 ($ billions)
Exhibit 37: Grifols: Geographical segmentation by revenue 2013
Exhibit 38: Octapharma: Product offerings


Baxter, CSL Behring, Grifols Therapeutics, Octapharma, Abeona Therapeutics, ADMA Biologics, Amag Pharmaceuticals, Antares Pharma, BioDelivery Sciences, Bio Products Laboratory, Biota Pharmaceuticals, Biotest Pharmaceuticals, China Biologic Products, Depomed, Emergent BioSolutions, Ethicon, Flamel Technologies, Kamada, Kedrion, King Pharmaceuticals, Nektar Therapeutics, OMRIX Biopharmaceuticals, ProMetic Life Sciences, Rockwell Medical, The Medicines, ZymoGenetics





★調査レポート[血漿交換療法の世界市場2015-2019] (Global Plasma Therapeutics Market 2015-2019 / IRTNTR6802)販売に関する免責事項
[血漿交換療法の世界市場2015-2019] (Global Plasma Therapeutics Market 2015-2019 / IRTNTR6802)についてEメールでお問い合わせ